Literature DB >> 32864325

Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety.

Alan K Davis1,2, Frederick S Barrett2, Roland R Griffiths2,3.   

Abstract

Prior research has shown that acute subjective psychedelic effects are associated with both spontaneous and intended changes in depression and anxiety. Psychedelics are also theorized to produce increases in psychological flexibility, which could explain decreases in depression and anxiety following a psychedelic experience. Therefore, the present cross-sectional survey study sought to examine whether psychological flexibility mediated the relationship between acute psychedelic experiences and spontaneous or intended changes in depression and anxiety among a large international sample of people who reported having used a psychedelic (n=985; male=71.6%; Caucasian/white=84.1%; M age=32.2, SD=12.6). A regression analysis showed that acute effects (i.e., mystical and insightful effects) were significantly associated with decreases in depression/anxiety following a psychedelic experience. A path analysis revealed that, while controlling for age and sex, increases in psychological flexibility fully mediated the effect of mystical and insightful experiences on decreases in depression and anxiety following a psychedelic experience. This suggests that psychological flexibility may be an important mediator of the therapeutic effects of psychedelic drugs. Future prospective experimental studies should examine the effect of psychedelic drug administration on psychological flexibility in order to gain a better understanding of the psychological processes that predict therapeutic effects of psychedelics.

Entities:  

Keywords:  anxiety; depression; hallucinogens; mechanism; psychedelics; psychological flexibility

Year:  2019        PMID: 32864325      PMCID: PMC7451132          DOI: 10.1016/j.jcbs.2019.11.004

Source DB:  PubMed          Journal:  J Contextual Behav Sci


  50 in total

1.  The phenomenon of quantum change.

Authors:  William R Miller
Journal:  J Clin Psychol       Date:  2004-05

2.  Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.

Authors:  Frederick S Barrett; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2015-10-06       Impact factor: 4.153

Review 3.  Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.

Authors:  Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-18

4.  The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.

Authors:  Alan K Davis; Joseph P Barsuglia; Rafael Lancelotta; Robert M Grant; Elise Renn
Journal:  J Psychopharmacol       Date:  2018-04-30       Impact factor: 4.153

5.  A meta-analysis of the efficacy of acceptance and commitment therapy for clinically relevant mental and physical health problems.

Authors:  Jacqueline G L A-Tjak; Michelle L Davis; Nexhmedin Morina; Mark B Powers; Jasper A J Smits; Paul M G Emmelkamp
Journal:  Psychother Psychosom       Date:  2014-12-24       Impact factor: 17.659

Review 6.  The clinical effectiveness of CBT-based guided self-help interventions for anxiety and depressive disorders: a systematic review.

Authors:  G Coull; P G Morris
Journal:  Psychol Med       Date:  2011-06-15       Impact factor: 7.723

Review 7.  The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review.

Authors:  Mark Sinyor; Ayal Schaffer; Anthony Levitt
Journal:  Can J Psychiatry       Date:  2010-03       Impact factor: 4.356

8.  The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories.

Authors:  P F Lovibond; S H Lovibond
Journal:  Behav Res Ther       Date:  1995-03

Review 9.  Epidemiology and treatment of depression in patients with chronic medical illness.

Authors:  Wayne J Katon
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

10.  Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.

Authors:  Leor Roseman; David J Nutt; Robin L Carhart-Harris
Journal:  Front Pharmacol       Date:  2018-01-17       Impact factor: 5.810

View more
  40 in total

Review 1.  Sustained effects of single doses of classical psychedelics in humans.

Authors:  Gitte M Knudsen
Journal:  Neuropsychopharmacology       Date:  2022-06-21       Impact factor: 7.853

2.  Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil.

Authors:  Dimitri Daldegan-Bueno; Lucas Oliveira Maia; Carolina Marcolino Massarentti; Luís Fernando Tófoli
Journal:  Psychopharmacology (Berl)       Date:  2022-02-18       Impact factor: 4.530

3.  Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial).

Authors:  Mathias Ebbesen Jensen; Dea Siggaard Stenbæk; Tobias Søgaard Juul; Patrick MacDonald Fisher; Claus Thorn Ekstrøm; Gitte Moos Knudsen; Anders Fink-Jensen
Journal:  BMJ Open       Date:  2022-10-14       Impact factor: 3.006

Review 4.  Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default.

Authors:  David B Yaden; Dylan Earp; Marianna Graziosi; Dara Friedman-Wheeler; Jason B Luoma; Matthew W Johnson
Journal:  Front Psychol       Date:  2022-05-23

5.  Increased Entropic Brain Dynamics during DeepDream-Induced Altered Perceptual Phenomenology.

Authors:  Antonino Greco; Giuseppe Gallitto; Marco D'Alessandro; Clara Rastelli
Journal:  Entropy (Basel)       Date:  2021-06-30       Impact factor: 2.524

6.  Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes.

Authors:  Gabrielle Agin-Liebes; Trevor F Haas; Rafael Lancelotta; Malin V Uthaug; Johannes G Ramaekers; Alan K Davis
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-23

Review 7.  Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects.

Authors:  Jacob S Aday; Alan K Davis; Cayla M Mitzkovitz; Emily K Bloesch; Christopher C Davoli
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-05

Review 8.  Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice.

Authors:  Jake E Payne; Richard Chambers; Paul Liknaitzky
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-16

9.  Using Psychedelics With Therapeutic Intent Is Associated With Lower Shame and Complex Trauma Symptoms in Adults With Histories of Child Maltreatment.

Authors:  C J Healy; Kellie Ann Lee; Wendy D'Andrea
Journal:  Chronic Stress (Thousand Oaks)       Date:  2021-07-11

10.  Sustained, Multifaceted Improvements in Mental Well-Being Following Psychedelic Experiences in a Prospective Opportunity Sample.

Authors:  Keri Mans; Hannes Kettner; David Erritzoe; Eline C H M Haijen; Mendel Kaelen; Robin L Carhart-Harris
Journal:  Front Psychiatry       Date:  2021-06-29       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.